New Wave Holdings Corp. funds Delos Psyche to back LSD research
Category: #health  By Mateen Dalal  Date: 2020-06-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

New Wave Holdings Corp. funds Delos Psyche to back LSD research

New Wave Holdings Corp., a Canadian company that focuses on entertainment and esports facilities, has recently announced that it would support the Delos Psyche Research Group in its research on determining the impact of small ingestions of psychedelic or hallucinogenic substances like lysergic acid diethylamide (LSD) for therapeutic or medicinal purposes.

According to reliable sources, the motive behind this observational study is to find few of the impacts of microdosing LSD on patients suffering from anxiety, depression, stress, along with several other clinical constructs.  The study also intends to determine its effect on positive psychological constructs. This research would employ a naturalistic setting as well as a 3-day dosing cycle over a 30-day timeframe.

Speaking on the move, Trumbull Fisher, President, New Wave Holdings, said that the company is pleased to back Delos Psyche in its research and is looking ahead to working with Delos’s team as they commence this new study. This is a significant step forward to introducing psychedelic therapies to those people who really need it and may greatly benefit from it, claims Fisher.

For the record, microdosing is a practice of consuming small, sub-hallucinogenic portions of psychedelic materials like psilocybin, mescaline, or LSD. It has turned out to be a very popular practice, especially for people who are working in the technology sector, where it is usually consumed to increase motivation, focus, creativity, and quality of relationships.

In other news, neuro-pharmaceutical company Mind Medicine recently made a significant stride in the psychedelic sector when it launched its commercial drug development program, Project Lucy. The program intends to find a treatment for anxiety disorders.

Evidently, Mind Medicine is set to start a Phase 2b human efficacy study that would emphasize on experiential doses of LSDs under the supervision of a therapist. This would be the first psychedelic-assisted, experiential therapy to be added to the company’s drug development pipeline.

Source Credit: https://www.prnewswire.com/news-releases/new-wave-holdings-corp-provides-funding-for-lsd-research-study-301071139.html

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AI-centric study abroad platform Edvoy launched by IEC Abroad in India
AI-centric study abroad platform Edvoy launched by IEC Abroad in India
By Mateen Dalal

AI oriented study abroad platform, Edvoy, based out of UK, has reportedly declared its launch in India.  Edvoy, created by IEC Abroad, is a free digital platform that provides impartial advice, support, and content to prospective international s...

Centuria announces Augusta Capital takeover offer to be unconditional
Centuria announces Augusta Capital takeover offer to be unconditional
By Mateen Dalal

  Acceptance to takeover represent 65.86% of Augusta’s shares Takeover provide shareholders with NZ$0.22 in cash and 0.392 Centuria stapled securities for every share of Augusta Centuria’s assets under management will increase b...

High likeliness of COVID-19 damaging the brain, claim scientists
High likeliness of COVID-19 damaging the brain, claim scientists
By Mateen Dalal

The advent of COVID-19 has turned out to be one of worst disasters the world has seen in recent times. In an attempt to thwart its spread, myriad efforts are being undertaken, along the likes of social distancing, nationwide lockdowns, vaccine resear...